Disrupting membrane lipids composition promotes tumorigenesis: the other dark side of cholesterol and the potential implication of gangliosides
Editorial

Disrupting membrane lipids composition promotes tumorigenesis: the other dark side of cholesterol and the potential implication of gangliosides

Tony Lefebvre, Philippe Delannoy

Structural and Functional Glycobiology Unit, UMR CNRS 8576, University of Lille, Lille, France

Correspondence to: Philippe Delannoy. Structural and Functional Glycobiology Unit, UMR CNRS 8576, University of Lille, Lille, France. Email: philippe.delannoy@univ-lille.fr.

Provenance: This is an invited Editorial commissioned by Section Editor Yan Li (Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore).

Comment on: Wang B, Rong X, Palladino EN, et al. Phospholipid Remodeling and Cholesterol Availability Regulate Intestinal Stemness and Tumorigenesis. Cell Stem Cell 2018;22:206-20.e4.


Submitted Apr 05, 2018. Accepted for publication Apr 18, 2018.

doi: 10.21037/tcr.2018.04.26


Within the four major families of biological compounds, lipids are likely the most unknown. This nescience is partly due to their structure heterogeneity when compared to carbohydrates, proteins and nucleic acids that inside the same family share similar structural features, and to the negative press that is done to them. However and despite this contempt, lipids are fundamental building blocks for cell shape and constitute the most important energy tank. Lack of knowledge of their benefits makes us forget that they also support a myriad of biological functions they endorse in the form of fat-soluble vitamins, steroid hormones (corticoids and sex steroids), pheromones, odors, second messengers (inositides, ceramides), and post-translational modifications (acylation, prenylation, cholesteroylation).

More than any other lipids considered unloved, cholesterol appears as the common enemy of Western societies, as evidenced by the great advertising support that is supposed to learn people how to fight it. Indeed, excess cholesterol is long-standing known to be a major actor of atherosclerosis responsible for the two main causes of deaths worldwide, ischemic heart disease and ischemic stroke, and characterized by accumulation of cholesterol with macrophages in blood vessel walls. Less known is the involvement of lipid metabolism disruption in tumorigenesis albeit it was long been observed that nutrient excess, consumption of cholesterol increased gastrointestinal cancer (1). A recent paper from the group of Peter Tontonoz (University of California, Los Angeles, USA) (2) points out the reciprocal relationship between the availability of cholesterol on the proliferation of intestinal stem cells (ISCs) and the activity of the phospholipid-remodeling enzyme lysophosphatidylcholine acyltransferase 3 (Lpcat3), an enzyme the authors identified as pivotal for membrane phospholipids composition (3). Interestingly, previous independent studies focusing phospholipase A2 (PLA2), an enzyme that hydrolyzes the acyl group at position sn-2 of phospholipids, and belonging as well as Lpcat3 to Lands’ cycle, reported that this enzyme aggravates emergence of intestinal tumors in Apc mice, a model in which the ApcMin mutation disrupts the mouse homologue of the human familial polypose gene, thus developing intestinal tumors (4,5). Based on these observations, Wang and collaborators reasoned that since (I) a fraction of ISCs give progenitors that in turn move from the crypt to the intestinal villi and differentiate into all cell types needed for gut function, and that (II) ISCs are at the origin for intestinal tumors developing in mice harboring APC mutations, a remodeling of phospholipid should be partly responsible for tumorigenesis. The authors took advantage of the two following animal models: first, tamoxifen-inducible intestine-specific Lpcat3 deficient mice generated by crossing Lpcat3fl/fl with Villin-CreERT2, and a second one generated by crossing the former with Apcmin mice. Then, they showed that a deficiency in Lpcat3 enhances proliferation of the ISCs via an increase in cholesterol biosynthesis. Previously, studies proposed that remodeling of phospholipids promotes intestinal tumorigenesis but without elucidating the mechanism. In this way, in Apcmin mice, over-expression of the secretory/membrane-bound phospholipase Pla2g2a reduces tumor number and enhances tumor resistance (6). In contrast, loss of the phospholipase increased tumor formation (7). Nevertheless, none of these studies pointed out the potential involvement of cholesterol in intestinal tumor emergence. Wang and collaborators undertook a gene ontology analysis in Lpcat3-deficient crypts that unveiled an increased-expression of genes responsible for cholesterol biosynthesis, and consequently a higher amount of free cholesterol. Mice deficient for Lpcat3 exhibited nuclear accumulation of the transcription factor SREBP-2, a master driver of cholesterol biosynthesis, making sense to the monitoring of enhanced cholesterol. These observations were strengthened by use of cholesterol inhibitors such as simvastatin and Ro48, an inhibitor of lanosterin synthase. The latter when administered to Lpcat3 deficient mice significantly reduced the height of the crypts, proliferation of cells in jejunum crypts and expression of the Olfm4 specific ISC marker. At last, by generating Srebf2 Tg Apcmin/+ mice, it was observed that these mice developed more tumors than Apcmin/+ control. Therefore, the paper concludes that in response to phospholipid remodeling, cholesterol acts as a mitogen: cholesterol is an active actor of ISC proliferation and in all likelihood an initiator of intestinal tumorigenesis. Yet, a major point, not least, remains to be elucidated: how the remodeling of phospholipids affects the synthesis of cholesterol. A possible explanation would be that SREBP-2 subcellular localization is perturbed in conditions of decreased activity of Lpcat3. The authors showed that Lpcat3 deficiency dramatically increases localization of SREBP-2 in the nucleus. However, a disturbance in the membrane of the endoplasmic reticulum (ER), in which many enzymes responsible for cholesterol synthesis including HMG-CoA reductase and lanosterin synthase are located, and of Golgi apparatus has not been envisioned by the authors. All three members of the SREBP family, SREBP-1a, SREBP-1c, and SREBP-2 are generated as inactive precursors embedded in the membrane of the ER. Maturation of these precursors requires their translocation from the ER to the Golgi membrane where are located the proteases S1P and S2P (site-1 and site-2 proteases) that cleave SREBP-2 precursor into matured fragments. Two factors control this process: the protein SCAD capable to sense cholesterol and derivatives concentration, and the inhibitory protein Insig to which SCAP binds. SCAP and Insig therefore prevent SREBPs to reach the Golgi. In conditions of low cholesterol, SREBP-2 is translocated into the nucleus where it associates to sterol regulatory element (SRE) found in promoters of genes encoding LDLR (cholesterol uptake) and enzymes involved in cholesterol biosynthesis including the key-rate limiting enzyme HMG-CoA reductase. A remodeling of ER to Golgi phospholipids may result in a default of processing and subcellular location of SREBP-2, and to a disturbed transport in the nucleus.

Phospholipids and cholesterol are not the only ones to play a leading role in membrane dynamics and architecture. Glycosphingolipids (GSLs) are essential compounds for the organization, the maintenance and the functions of lipid rafts (lipid microdomains) in plasma membrane. Cholesterol is rather equally distributed between the two leaflets of the plasma membrane: it interacts preferentially with phosphatidylethanolamine and phosphatidylserine in the inner leaflet and with phosphatidylcholine and sphingomyelin in the outer one. Importantly, cholesterol also needs interactions with GSLs, especially gangliosides, the sialic acid containing GSLs, exclusively found in the outer leaflet. Within the membrane these components tightly interact through their hydrophobic lateral chains to cluster in lipid rafts. In a somewhat disappointing way, while investigating lipid composition disruption in ISCs, Wang and collaborators did not look at the levels of GSLs/gangliosides. Yet and in the context of the paper, highly proliferative cells like cancer cells are not only characterized by the need of an accelerated biosynthesis of lipid compounds so as to respond to increased membrane surface, but also by the necessity to remodel lipid rafts. Lipid rafts are crucial for signal transduction and cell signaling since they gather together receptors tyrosine kinases (RTKs) such as growth factor receptors and intracellular signaling components of mitogen pathways (8). Thus, within lipid rafts gangliosides interact with signaling molecules including RTKs and integrins, transmembrane receptors particularly active in signal transduction. Even if to date no data regarding Lpcat3 and gangliosides are available, a connection between this group of GSLs and lysophosphatidylcholine was drawn. It was reported that lysophosphatidylcholine-stimulated EGF signaling is inhibited by GM3 strengthening the role of gangliosides in cell transduction (9). Therefore, interactions between gangliosides and RTKs play an important role in the fine tuning of signal transduction by regulating RTK signaling (10). A large number of reports have underlined the role of complex gangliosides, especially GD3 and GD2, in several cancers from neuro-ectoderm origin, such as melanoma or neuroblastoma. These papers demonstrated the implication of complex gangliosides in cell proliferation, migration, tumor growth and angiogenesis. The effects mainly result from the interaction of complex gangliosides with signaling molecules as it was clearly demonstrated in melanoma where GD3 expression results in a high level of phosphorylation and activation of the major adaptor proteins paxillin, p130Cas and FAK (11). In breast cancer cells, the expression of the GD3S and complex gangliosides results in the acquisition of higher proliferative capacity of tumor cells in the absence of growth factors. GD3S expressing cells bypass the need of growth factors by a specific and constitutive activation of c-Met receptor and activation of PI3K/Akt and Erk/MAPK pathways. GD3S expression also enhanced tumor growth in SCID mice, and a higher expression of ST8SIA1 in “basal-like” sub-type of human breast tumors was observed (12). The decrease of GD2 expression by silencing of the GM2/GD2 synthase or competition assays using anti-GD2 mAbs reversed the proliferative phenotype as well as c-Met phosphorylation (13) demonstrating the involvement of GD2 in breast cancer cell proliferation via the constitutive activation of c-Met.

According to their expression pattern and localization, GSLs including stage-specific embryonic antigens (SSEA)-3 and SSEA-4, and complex gangliosides such as GD3 and GD2, have been used as stem cells markers, including cancer stem cells (CSCs) (14). Recently, the disialoganglioside GD2 was identified as a new specific cell surface marker of CD44hiCD24lo breast CSCs from human breast cancer cell lines and patient samples that are capable of forming mammospheres and initiating tumors (15). Gene expression analysis revealed that several glycosyltransferases encoding genes involved in GD2 biosynthesis (ST3GAL5, B4GALNT1, and ST8SIA1) are highly expressed in CSCs (15,16). The reduction of GD2 expression by ST8SIA1 knockdown reduced mammosphere formation and cell motility, and completely abrogated tumor formation in vivo, changing the phenotype from CSC to non-CSC (15,16). Moreover, the induction of epithelial-mesenchymal transition (EMT) in transformed human mammary epithelial cells dramatically increased GD3 synthase (GD3S) as well as GD2 expression, whereas the inhibition of GD3S compromised EMT initiation and maintenance and prevented metastasis (17). High-grade bladder cancer (BLCA) cells also show high expression of GD2 together with a mesenchymal and proliferative phenotype, and CSC properties (18).

GD3S alone can sustain CSC properties and promote malignant cancer characteristics. GD3 was shown to be associated with epithelial growth factor receptor (EGFR) and activated EGFR signaling in breast CSCs. In parallel, GD3S knockdown enhanced cytotoxicity of Gefitinib in resistant cells, showing that GD3S can contribute to Gefitinib-resistance in EGFR-positive breast cancer cells (19). GD3S and GD3 disialoganglioside are also highly expressed in glioblastoma multiforme (GBM) CSCs (GSC), a grade IV astrocytoma, playing a key role in glioblastoma tumorigenicity. GD3S is increased in neurospheres and human GBM tissues, but not in normal brain tissues, and suppression of GD3S results in decreased GSC-associated properties. In addition, anti-GD3 mAbs induce inhibition of GBM tumor growth in vivo (20).

Altogether, these findings underline the role of gangliosides in CSC maintenance and properties, as well as in tumorigenicity and tumor formation. According to the important role of phospholipids and cholesterol in lipid raft formation, it would be really interesting to address the question of lipid raft function in ISCs activation in Lpcat3 deficient mice and the relationship between cholesterol biosynthesis and lipid raft organization in this process. In this way, a tentative link has been drawn between cholesterol and gangliosides. It was shown that lack of GM2/GD2 synthase dramatically reduced accumulation of cholesterol (21). Like part of SREBP-2 processing, GD2 and GD3 synthases are localized in the Golgi. Perturbing phospholipids composition may affect gangliosides synthesis as it should interfere with SREBP-2 maturation. Nevertheless, a second study indicated that biosynthesis and concentration of cholesterol were unaffected in animals lacking GM2/GD2 synthase concluding that plasma membrane cholesterol status is unaffected by gangliosides (22). It is to note that both studies were performed in neurological diseases models, far from the topic of the paper from Wang and collaborators, since while gangliosides are distributed in all cell types, they are more abundant in the cells of the central nervous system. Therefore, more have to be done to determine whether gangliosides and cholesterol metabolisms are linked and if it has an impact on intestinal tumorigenesis.


Acknowledgements

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Järvinen R, Knekt P, Hakulinen T, et al. Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer 2001;85:357-61. [Crossref] [PubMed]
  2. Wang B, Rong X, Palladino EN, et al. Phospholipid Remodeling and Cholesterol Availability Regulate Intestinal Stemness and Tumorigenesis. Cell Stem Cell 2018;22:206-20.e4. [Crossref] [PubMed]
  3. Rong X, Albert CJ, Hong C, et al. LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell Metab 2013;18:685-97. [Crossref] [PubMed]
  4. Dietrich WF, Lander ES, Smith JS, et al. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 1993;75:631-9. [Crossref] [PubMed]
  5. MacPhee M, Chepenik KP, Liddell RA, et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995;81:957-66. [Crossref] [PubMed]
  6. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997;17:88-91. [Crossref] [PubMed]
  7. Kennedy BP, Payette P, Mudgett J, et al. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J Biol Chem 1995;270:22378-85. [Crossref] [PubMed]
  8. Mollinedo F, Gajate C. Lipid rafts as major platforms for signaling regulation in cancer. Adv Biol Regul 2015;57:130-46. [Crossref] [PubMed]
  9. Igarashi Y, Kitamura K, Zhou QH, et al. A role of lyso-phosphatidylcholine in GM3-dependent inhibition of epidermal growth factor receptor autophosphorylation in A431 plasma membranes. Biochem Biophys Res Commun 1990;172:77-84. [Crossref] [PubMed]
  10. Furukawa K, Ohkawa Y, Yamauchi Y, et al. Fine tuning of cell signals by glycosylation. J Biochem 2012;151:573-8. [Crossref] [PubMed]
  11. Hamamura K, Furukawa K, Hayashi T, et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci USA 2005;102:11041-6. [Crossref] [PubMed]
  12. Cazet A, Lefebvre J, Adriaenssens E, et al. GD3 synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 2010;8:1526-35. [Crossref] [PubMed]
  13. Cazet A, Bobowski M, Rombouts Y, et al. The ganglioside GD2 induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the GD3 synthase. Glycobiology 2012;22:806-16. [Crossref] [PubMed]
  14. Yanagisawa M.. Stem cell glycolipids. Neurochem Res 2011;36:1623-35. [Crossref] [PubMed]
  15. Battula VL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis J Clin Invest 2012;122:2066-78. [Crossref] [PubMed]
  16. Liang YJ, Ding Y, Levery SB, et al. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs cancer non-stem cells. Proc Natl Acad Sci USA 2013;110:4968-73. [Crossref] [PubMed]
  17. Sarkar TR, Battula VL, Werden SJ, et al. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 2015;34:2958-67. [Crossref] [PubMed]
  18. Vantaku V, Donepudi SR, Ambati CR, et al. Expression of ganglioside GD2 reprogram the lipid metabolism and EMT phenotype in bladder cancer. Oncotarget 2017;8:95620-31. [Crossref] [PubMed]
  19. Liang YJ, Wang CY, Wang IA, et al. Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget 2017;8:47454-73. [PubMed]
  20. Yeh SC, Wang PY, Lou YW, et al. Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity. Proc Natl Acad Sci USA 2016;113:5592-7. [Crossref] [PubMed]
  21. Gondré-Lewis MC, McGlynn R, Walkley SU. Cholesterol accumulation in neurons with NPC1 dysfunction is ganglioside-dependent. Current Biology 2003;13:1324-9. [Crossref] [PubMed]
  22. Li H, Turley SD, Liu B, et al. GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice. J Lipid Res 2008;49:1816-28. [Crossref] [PubMed]
Cite this article as: Lefebvre T, Delannoy P. Disrupting membrane lipids composition promotes tumorigenesis: the other dark side of cholesterol and the potential implication of gangliosides. Transl Cancer Res 2018;7(Suppl 5):S587-S590. doi: 10.21037/tcr.2018.04.26